On September 16, 2022, the "2021 China Biopharmaceutical Enterprise Innovation Top 100 Series List" officially announced, Frontier Biotechnologies Inc. (stock code "688221.SH") was once again successfully included as "China's Top 30 Small Molecule Pharmaceutical Enterprises Innovation".

As a leading Chinese innovative pharmaceutical company, Frontier Biotech has been selected as one of the Top 30 Innovative Companies in China for two consecutive years. This industry's recognition acknowledges the company’s ongoing commitment and contributions in developing innovative medicines. With more than 20 years of experience, Frontier Biotech has the expertise in the development of antiviral and peptide innovative medicines. Pioneering in building breakthrough platforms including a long-acting polypeptide technology platform and a new transdermal patch preparation technology platform. The Company is expanding its clinical program for several innovative pipelines products including a long-acting innovative combination therapy for HIV (FB1002) and a small molecule treatment for COVID-19 (FB2001), etc.